Metatron (MRNJ) Integrates New Cryptocurrency App
Post# of 617763
DOVER, DE--(Marketwired - Nov 29, 2017) - Metatron (
Metatron recently signed a deal with a Sanguine Biotech to manage and integrate certain technologies within the Cannaboids™ app, more news about this agreement forthcoming. Sanguine has developed a network of 20,000 patients, including 50+ patient advocacy group non-profits, biobanks, and patient portals. Here is a list of their data and specimens used in 40+ peer-reviewed journal articles .
This announcement coincides with the launch of http://www.icocryptoblockchain.com , the premier one-stop website soon to be app with the latest cryptocurrency news, editorials, market capitalizations, trade volume and ICO alerts.
According to industry estimates, Bitcoin and the 1000+ alt coins are now worth over $300 billion, only a year ago they were worth about 1 billion. Today over $10 billion in digital tokens change hands daily and even big players such as Goldman Sachs, Visa, Capital One, Nasdaq, and the New York Stock Exchange have invested in blockchain technology.
"With Cannabis legal in about 29 states and Bitcoin's watershed moment of crossing $10,000 yesterday, it certainly seems like we are seeing a shift from the early adopter phase and into the mainstream phase for both industries. Payment solutions are needed for dispensaries and other related services so we plan on integrating the upcoming Bitweed™ and the current popular Cannaboids™ apps to make this process more efficient for retailers and customers," said CEO Joe Riehl.
According to Forbes, by 2020 the Cannabis industry is expected to create more jobs than manufacturing. Overall legal marijuana sales are set to increase from about 7 billion dollars in 2016 to 26.5 billion dollars by 2020. If Canada legalizes recreational marijuana nationwide, which seems likely, it will result in an additional 23 billion dollars added to the industry over the same time period according to Deloitte.
Metatron, an industry leader in the field of mobile app development with over 2000 apps created, millions in sales and downloads historically, has partnered with high profile companies and clients worldwide and is poised to revolutionize the exploding crypto and cannabis industries.
Through its app development division i-Mobilize™, and as a pioneer in emerging markets, Metatron was the first company to release any Cannabis related apps on iTunes and has extensive experience in processing payments through its Just Data Billing division. Release date for the BitWeed™ app is expected first quarter of next year.
Metatron is also pleased to announce a formal offer to Buzzlink.com, a cannabis e-commerce platform for dispensaries and other retailers. Buzzlink.com will be financed partially by the issuance of preferred B series shares.
Metatron approved investors can acquire Series B shares in blocks of various sizes. The first round investors will receive the highest discount. Series B shares can be redeemed through the Company, are immune to reverse splits, and will convert at 1 B share to 50,000 common shares at a discount. There are a limited number of B shares available and Metatron reserves the right to end offering at any time.
Details available at: http://metatroninc.com/series-b/
Metatron's Apps: iTunes: https://itunes.apple.com/us/artist/i-mobilize...d325075390
Google Play: https://play.google.com/store/apps/developer?id=Metatron+Inc
Facebook: http://www.facebook.com/metatroninc Twitter: http://twitter.com/metatroninc News: http://metatroninc.com/blog
Forward-Looking Statements:
Any statements made in this press release which are not historical facts contain certain forward-looking statements, as such term is defined in the Private Litigation Reform Act of 1995, concerning potential developments affecting the business, prospects, financial condition and other aspects of the company to which this release pertains. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results of the specific items described in this release, and the company's operations generally, to differ materially from what is projected in such forward-looking statements. Although such statements are based upon the best judgments of management of the company as of the date of this release, significant deviations in magnitude, timing and other factors may result from business risks and uncertainties including, without limitation, the company's need for additional financing, which is not assured and which may result in dilution of shareholders, the company's status as a small company with a limited operating history, dependence on third parties and the continuing popularity of the iOS operating system, general market and economic conditions, technical factors, receipt of revenues, and other factors, many of which are beyond the control of the company. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements, and we disclaim any obligation to update information contained in any forward-looking statement. Metatron does not grow, sell or distribute any substances that violate United States Law or the Controlled Substances Act.
Contact: Metatron, Inc. 302-861-0431 ir@metatroninc.com
(0)
(0)